SCHEMBL6993039

SCHEMBL6993039

Fc1ccc2c(c1)Nc1sc3ccccc3c1C(N1CCNCC1)=N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.47
HTR2C P28335 3/20 0.47
CHRM2 P08172 3/20 0.47
CHRM4 P08173 3/20 0.47
CHRM5 P08912 3/20 0.47
CHRM1 P11229 3/20 0.47
CHRM3 P20309 3/20 0.47
DRD1 P21728 3/20 0.47
KCNH2 Q12809 3/20 0.47
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
ADRA1D P25100 2/20 0.47
HTR2A P28223 2/20 0.47
ADRA1A P35348 2/20 0.47
HRH1 P35367 2/20 0.47
ADRA1B P35368 2/20 0.47
HTR2B P41595 2/20 0.47
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6990220 0.89 CHRM1 (0.49) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL8123379 0.87 HTR1A (0.37) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL7002700 0.86 CHRM1 (0.38) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL6990191 0.86 CHRM1 (0.39) CHRM1HRH1
SCHEMBL6994692 0.85 CHRM1 (0.52) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL6999455 0.85 CHRM1 (0.46) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL7967911 0.84 TP53 (0.40) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL6995628 0.84 HRH4 (0.43) DRD2HTR2CCHRM2CHRM4CHRM5
SCHEMBL7001523 0.84 DRD2 (0.41) DRD2DRD1HTR3EMEN1HTR3B
SCHEMBL6989206 0.84 CHRM1 (0.39) DRD2HTR2CCHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT DRD2 620/4885HTR2C 443/4885CHRM2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.